Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3115MR)

This product GTTS-WQ3115MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3115MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15973MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ3590MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ14553MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ10892MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ9766MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ11702MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ13453MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ13181MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW